CA2652600A1 - Utilisation d'antagonistes de la cathepsine k dans la production osseuse - Google Patents

Utilisation d'antagonistes de la cathepsine k dans la production osseuse Download PDF

Info

Publication number
CA2652600A1
CA2652600A1 CA002652600A CA2652600A CA2652600A1 CA 2652600 A1 CA2652600 A1 CA 2652600A1 CA 002652600 A CA002652600 A CA 002652600A CA 2652600 A CA2652600 A CA 2652600A CA 2652600 A1 CA2652600 A1 CA 2652600A1
Authority
CA
Canada
Prior art keywords
bone
cathepsin
inhibitor
cell
implant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002652600A
Other languages
English (en)
Inventor
Michael Long
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Velcura Therapeutics Inc
Original Assignee
Velcura Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Velcura Therapeutics Inc filed Critical Velcura Therapeutics Inc
Publication of CA2652600A1 publication Critical patent/CA2652600A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22038—Cathepsin K (3.4.22.38)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
CA002652600A 2006-05-22 2007-05-18 Utilisation d'antagonistes de la cathepsine k dans la production osseuse Abandoned CA2652600A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74788606P 2006-05-22 2006-05-22
US60/747,886 2006-05-22
US81045606P 2006-06-01 2006-06-01
US60/810,456 2006-06-01
PCT/US2007/069211 WO2007137149A2 (fr) 2006-05-22 2007-05-18 Utilisation d'antagonistes de la cathepsine k dans la production osseuse

Publications (1)

Publication Number Publication Date
CA2652600A1 true CA2652600A1 (fr) 2007-11-29

Family

ID=38724028

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002652600A Abandoned CA2652600A1 (fr) 2006-05-22 2007-05-18 Utilisation d'antagonistes de la cathepsine k dans la production osseuse

Country Status (5)

Country Link
EP (1) EP2019688A2 (fr)
JP (1) JP2010503610A (fr)
AU (1) AU2007253796A1 (fr)
CA (1) CA2652600A1 (fr)
WO (1) WO2007137149A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2752729A1 (fr) * 2009-02-20 2010-08-26 Ventria Bioscience Milieu de culture cellulaire contenant des combinaisons de proteines
JP2012148978A (ja) * 2009-09-24 2012-08-09 Nippon Chemiphar Co Ltd 歯周病又は根尖性歯周炎の予防又は治療剤
US20130157356A1 (en) * 2010-01-25 2013-06-20 Ventria Bioscience Methods & compositions for improving protein production
CN103381152A (zh) * 2013-02-05 2013-11-06 吉林省金梓源生物科技有限公司 杨梅素作为组织蛋白酶k抑制剂的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT826681E (pt) * 1995-03-31 2003-02-28 Nippon Chemiphar Co Derivados de acido epoxi-succinico
AU711014B2 (en) * 1995-10-30 1999-10-07 Smithkline Beecham Corporation Method of inhibiting cathepsin K
JP4336039B2 (ja) * 1997-09-04 2009-09-30 日本ケミファ株式会社 エポキシコハク酸アミド誘導体
SE516949C2 (sv) * 1999-12-30 2002-03-26 Scania Cv Ab Larmsystem för motorfordon
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
JP2005504040A (ja) * 2001-08-03 2005-02-10 スミスクライン ビーチャム コーポレーション カテプシンＫ阻害剤としてのα−ケトアミド誘導体
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
US7282512B2 (en) * 2002-01-17 2007-10-16 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors
JP2005532290A (ja) * 2002-04-10 2005-10-27 スミスクライン ビーチャム コーポレーション 骨喪失を治療するためのカテプシンｋ阻害剤としての１−（オキソアミノアセチル）ペンチルカルバマート誘導体

Also Published As

Publication number Publication date
EP2019688A2 (fr) 2009-02-04
WO2007137149A2 (fr) 2007-11-29
WO2007137149A3 (fr) 2008-02-14
JP2010503610A (ja) 2010-02-04
AU2007253796A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
US8299046B2 (en) Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
EP2167648B1 (fr) Procedes pour l'expansion et l'implantation optimisees de cellules souches mesenchymateuses
KR101688449B1 (ko) 생체 내에서 결합 조직을 생성, 복구 및/또는 유지하는 방법
EP2035549A1 (fr) Cellules souches mésenchymateuses positives abcb5 en tant qu'immunomodulateurs
Li et al. Bone marrow-derived mesenchymal stem cells in three-dimensional co-culture attenuate degeneration of nucleus pulposus cells
WO2013036875A1 (fr) Céramidase et différentiation cellulaire
CN103347497A (zh) 用于预防和治疗骨质疏松症和其它骨疾病的食品补充剂和可注射材料
EP3311809B1 (fr) Utilisation d'une composition pharmaceutique dans la préparation d'un médicament pour favoriser la génération de chondrocytes
CA2652600A1 (fr) Utilisation d'antagonistes de la cathepsine k dans la production osseuse
Xia et al. Matrigel scaffold combined with Ad-hBMP7-transfected chondrocytes improves the repair of rabbit cartilage defect
ES2304359T3 (es) Procedimiento de formacion ex vivo de hueso de mamiferos y usos del mismo.
Moioli et al. Autologous stem cell regeneration in craniosynostosis
JP2006514562A (ja) 試験管内で生産された三次元組織を組織細胞及び／又は外因性因子と組合わせて用いた罹患組織、変性組織又は損傷組織の治療方法
AU2003218463A1 (en) Bone generation by gene therapy
WO2009076490A1 (fr) Utilisation d'antagonistes de la cathepsine l dans le traitement de maladie des os
Wallmichrath et al. Epidermal growth factor (EGF) transfection of human bone marrow stromal cells in bone tissue engineering
WO2011007135A1 (fr) Procédés
US20070275462A1 (en) Human Prostate Cancer Cell Factor(s) that Induce Stem Cell Commitment and Osteogenesis
US20140286916A1 (en) Uses of Growth and Differentiation Factor 8 (GDF-8)
CN105940011A (zh) 用于治疗软骨和椎间盘组织病变的方法和组合物
WO2010021162A1 (fr) Préparation de cellules pour régénération de tissu osseux
US20230010110A1 (en) Histatin-1 formulation for the treatment, repair or regeneration of bone tissue in a subject
TWI395592B (zh) 由聚乳酸－甘醇酸（ｐｏｌｙ（ｌａｃｔｉｃ－ｃｏ－ｇｌｙｃｏｌｉｃ ａｃｉｄ））微小球控制釋放副甲狀腺素之方法
CN106366176A (zh) Pth模拟肽及其应用
Haddley Hypophosphatasia: New advances

Legal Events

Date Code Title Description
FZDE Dead